Overview

PREventing Progression of Adipose Tissue Redistribution

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The main objective of the study is to assess changes in fat distribution over 48 weeks of treatment in patients who currently successfully use zidovudine (AZT) and lamivudine (3TC) as part of their regimen and who will either continue these antiretrovirals or who will switch these antiretrovirals to tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Each of these medications is commonly used for the treatment of HIV-1 infection.
Phase:
Phase 4
Details
Lead Sponsor:
International Antiviral Therapy Evaluation Center
Collaborator:
Gilead Sciences
Treatments:
Lamivudine, zidovudine drug combination
Tenofovir